Results 221 to 230 of about 6,340,743 (257)

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study. [PDF]

Curr Oncol
Uccello M, Gee AL, Bennett JA, Hazell HL, Ruiz-Echarri Rueda M, Beresford MJ.   +5 more
europepmc   +1 more source

Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations. [PDF]

Cancer Rep (Hoboken)
Sakurai H, Shiga M, Kandori S, Takahashi S, Omiya A, Ishida T, Matsuda K, Isoda B, Mathis BJ, Komine M, Iinuma M, Joraku A, Negoro H, Tsutsumi M, Inoue T, Miyazaki J, Nishiyama H.   +16 more
europepmc   +1 more source

Early dynamics of eosinophils and the neutrophil-to-lymphocyte ratio are associated with severe immune-related adverse events during nivolumab therapy for metastatic renal cell carcinoma. [PDF]

Front Immunol
Fiala O, Králíček J, Kopecký J, Vočka M, Buchler T, Študentová H, Obertová J, Rondzíková B, Matějů M, Šafčák D, Hrnčár M, Priester P, Spisarová M, Zemánková A, Lohynská R, Tkadlecová M, Grmelová L, Stránský P, Melichar B, Palacka P, Poprach A.   +20 more
europepmc   +1 more source

Real-world drivers of treatment choices in synchronous metastatic renal cell carcinoma. [PDF]

BJUI Compass
Almdalal T, Fahlén M, Harmenberg U, Ljungberg B, Lindskog M.   +4 more
europepmc   +1 more source

Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications. [PDF]

Int J Urol
Ishikawa Y, Tanaka H, Yamaguchi Y, Maruyama R, Fukuda S, Waseda Y, Inoue M, Yoshida S, Matsuoka Y, Numao N, Fujii Y.   +10 more
europepmc   +1 more source